Cancer Research and Treatment

Original Articles

Gastrointestinal cancer

Clinical Outcomes of Surgery after Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Ductal Adenocarcinoma: Yoo Na Lee, Min Kyu Sung, Dae Wook Hwang, Yejong Park, Bong Jun Kwak, Woohyung Lee, Ki Byung Song, Jae Hoon Lee, Changhoon Yoo, Kyu-Pyo Kim, Heung-Moon Chang, Baek-Yeol Ryoo, Song Cheol Kim; Cancer Res Treat. 2024;56(4):1240-1251. Published online June 19, 2024; DOI: https://doi.org/10.4143/crt.2023.977

Abstract PDF PubReader ePub: Purpose
Clinical outcomes of surgery after neoadjuvant chemotherapy have not been investigated for locally advanced pancreatic cancer (LAPC), despite well-established outcomes in borderline resectable pancreatic cancer (BRPC). This study aimed to investigate the clinical outcomes of patients with LAPC who underwent curative resection following neoadjuvant chemotherapy.
Materials and Methods
We retrospectively reviewed the records of patients diagnosed with pancreatic adenocarcinoma between January 2017 and December 2020.
Results
Among 1,358 patients, 260 underwent surgery following neoadjuvant chemotherapy. Among 356 LAPC patients, 98 (27.5%) and 147 (35.1%) of 418 BRPC patients underwent surgery after neoadjuvant chemotherapy. Compared to resectable pancreatic cancer (resectable PC) with upfront surgery, both LAPC and BRPC exhibited higher rates of venous resection (28.6% vs. 49.0% vs. 4.0%), arterial resection (30.6% vs. 6.8% vs. 0.5%) and greater estimated blood loss (260.5 vs. 213.1 vs. 70.4 mL). However, hospital stay, readmission rates, and postoperative pancreatic fistula rates (grade B or C) did not differ significantly between LAPC, BRPC, and resectable PC. Overall and relapse-free survival did not differ significantly between LAPC and BRPC patients. The median overall survival was 37.3 months for LAPC and 37.0 months for BRPC. The median relapse-free survival was 22.7 months for LAPC and 26.0 months for BRPC.
Conclusion
Overall survival time and postoperative complications in LAPC patients who underwent curative resection following neoadjuvant chemotherapy showed similar results to those of BRPC patients. Further research is needed to identify specific sub-populations of LAPC patients who benefit most from conversion surgery and to minimize postoperative complications.

2,252 View
108 Download

Analysis of Plasma Circulating Tumor DNA in Borderline Resectable Pancreatic Cancer Treated with Neoadjuvant Modified FOLFIRINOX: Clinical Relevance of DNA Damage Repair Gene Alteration Detection: Dong-Hoon Lim, Hyunseok Yoon, Kyu-pyo Kim, Baek-Yeol Ryoo, Sang Soo Lee, Do Hyun Park, Tae Jun Song, Dae Wook Hwang, Jae Hoon Lee, Ki Byung Song, Song Cheol Kim, Seung-Mo Hong, Jaewon Hyung, Changhoon Yoo; Cancer Res Treat. 2023;55(4):1313-1320. Published online May 4, 2023; DOI: https://doi.org/10.4143/crt.2023.452

Abstract PDF Supplementary Material PubReader ePub

Purpose
There are no reliable biomarkers to guide treatment for patients with borderline resectable pancreatic cancer (BRPC) in the neoadjuvant setting. We used plasma circulating tumor DNA (ctDNA) sequencing to search biomarkers for patients with BRPC receiving neoadjuvant mFOLFIRINOX in our phase 2 clinical trial (NCT02749136).
Materials and Methods
Among the 44 patients enrolled in the trial, patients with plasma ctDNA sequencing at baseline or post-operation were included in this analysis. Plasma cell-free DNA isolation and sequencing were performed using the Guardant 360 assay. Detection of genomic alterations, including DNA damage repair (DDR) genes, were examined for correlations with survival.
Results
Among the 44 patients, 28 patients had ctDNA sequencing data qualified for the analysis and were included in this study. Among the 25 patients with baseline plasma ctDNA data, 10 patients (40%) had alterations of DDR genes detected at baseline, inclu-ding ATM, BRCA1, BRCA2 and MLH1, and showed significantly better progression-free survival than those without such DDR gene alterations detected (median, 26.6 vs. 13.5 months; log-rank p=0.004). Patients with somatic KRAS mutations detected at baseline (n=6) had significantly worse overall survival (median, 8.5 months vs. not applicable; log-rank p=0.003) than those without. Among 13 patients with post-operative plasma ctDNA data, eight patients (61.5%) had detectable somatic alterations.
Conclusion
Detection of DDR gene mutations from plasma ctDNA at baseline was associated with better survival outcomes of pati-ents with borderline resectable pancreatic ductal adenocarcinoma treated with neoadjuvant mFOLFIRINOX and may be a prognostic biomarker.

Citations

Citations to this article as recorded by

A Review of Circulating Tumor DNA (ctDNA) in Pancreatic Cancer: Ready for the Clinic?
Purvi Jonnalagadda, Virginia Arnold, Benjamin A. Weinberg
Journal of Gastrointestinal Cancer.2025;[Epub] CrossRef
Blood-based biomarkers in pancreatic ductal adenocarcinoma: developments over the last decade and what holds for the future- a review
Ronit Juthani, Ashish Manne
Frontiers in Oncology.2025;[Epub] CrossRef
A Practical Approach to Interpreting Circulating Tumor DNA in the Management of Gastrointestinal Cancers
Zexi Allan, David S Liu, Margaret M Lee, Jeanne Tie, Nicholas J Clemons
Clinical Chemistry.2024; 70(1): 49. CrossRef
High somatic mutations in circulating tumor DNA predict response of metastatic pancreatic ductal adenocarcinoma to first-line nab-paclitaxel plus S-1: prospective study
Lei Huang, Yao Lv, Shasha Guan, Huan Yan, Lu Han, Zhikuan Wang, Quanli Han, Guanghai Dai, Yan Shi
Journal of Translational Medicine.2024;[Epub] CrossRef
Decoding the Dynamics of Circulating Tumor DNA in Liquid Biopsies
Khadija Turabi, Kelsey Klute, Prakash Radhakrishnan
Cancers.2024; 16(13): 2432. CrossRef
Building on the clinical applicability of ctDNA analysis in non-metastatic pancreatic ductal adenocarcinoma
Ibone Labiano, Ana E. Huerta, Maria Alsina, Hugo Arasanz, Natalia Castro, Saioa Mendaza, Arturo Lecumberri, Iranzu Gonzalez-Borja, David Guerrero-Setas, Ana Patiño-Garcia, Gorka Alkorta-Aranburu, Irene Hernández-Garcia, Virginia Arrazubi, Elena Mata, Davi
Scientific Reports.2024;[Epub] CrossRef
Liquid biopsy analysis of lipometabolic exosomes in pancreatic cancer
Wei Guo, Peiyao Ying, Ruiyang Ma, Zuoqian Jing, Gang Ma, Jin Long, Guichen Li, Zhe Liu
Cytokine & Growth Factor Reviews.2023; 73: 69. CrossRef

4,236 View
264 Download
6 Web of Science
7 Crossref

Survival Benefit of Adjuvant Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma Who Underwent Surgery Following Neoadjuvant FOLFIRINOX: So Heun Lee, Dae Wook Hwang, Changhoon Yoo, Kyu-pyo Kim, Sora Kang, Jae Ho Jeong, Dongwook Oh, Tae Jun Song, Sang Soo Lee, Do Hyun Park, Dong Wan Seo, Jin-hong Park, Ki Byung Song, Jae Hoon Lee, Woohyung Lee, Yejong Park, Bong Jun Kwak, Heung-Moon Chang, Baek-Yeol Ryoo, Song Cheol Kim; Cancer Res Treat. 2023;55(3):956-968. Published online February 27, 2023; DOI: https://doi.org/10.4143/crt.2022.409

Abstract PDF Supplementary Material PubReader ePub

Purpose
The benefit of adjuvant chemotherapy following curative-intent surgery in pancreatic ductal adenocarcinoma (PDAC) patients who had received neoadjuvant FOLFIRINOX is unclear. This study aimed to assess the survival benefit of adjuvant chemotherapy in this patient population.
Materials and Methods
This retrospective study included 218 patients with localized non-metastatic PDAC who received neoadjuvant FOLFIRINOX and underwent curative-intent surgery (R0 or R1) between January 2017 and December 2020. The association of adjuvant chemotherapy with disease-free survival (DFS) and overall survival (OS) was evaluated in overall patients and in the propensity score matched (PSM) cohort. Subgroup analysis was conducted according to the pathology-proven lymph node status.
Results
Adjuvant chemotherapy was administered to 149 patients (68.3%). In the overall cohort, the adjuvant chemotherapy group had significantly improved DFS and OS compared to the observation group (DFS: median, 13.8 months [95% confidence interval (CI), 11.0 to 19.1] vs. 8.2 months [95% CI, 6.5 to 12.0]; p < 0.001; and OS: median, 38.0 months [95% CI, 32.2 to not assessable] vs. 25.7 months [95% CI, 18.3 to not assessable]; p=0.005). In the PSM cohort of 57 matched pairs of patients, DFS and OS were better in the adjuvant chemotherapy group than in the observation group (p < 0.001 and p=0.038, respectively). In the multivariate analysis, adjuvant chemotherapy was a significant favorable prognostic factor (vs. observation; DFS: hazard ratio [HR], 0.51 [95% CI, 0.36 to 0.71; p < 0.001]; OS: HR, 0.45 [95% CI, 0.29 to 0.71; p < 0.001]).
Conclusion
Among PDAC patients who underwent surgery following neoadjuvant FOLFIRINOX, adjuvant chemotherapy may be associated with improved survival. Randomized studies should be conducted to validate this finding.

Citations

Citations to this article as recorded by

Prognostic factors in localized pancreatic ductal adenocarcinoma after neoadjuvant therapy and resection: a systematic review and meta-analysis
Ammar A Javed, Alyssar Habib, Omar Mahmud, Asad Saulat Fatimi, Mahip Grewal, Nabiha Mughal, Jin He, Christopher L Wolfgang, Lois Daamen, Marc G Besselink
JNCI: Journal of the National Cancer Institute.2025; 117(5): 840. CrossRef
The survival effect of neoadjuvant therapy and neoadjuvant plus adjuvant therapy on pancreatic ductal adenocarcinoma patients with different TNM stages: a propensity score matching analysis based on the SEER database
Hao Hu, Yang Xu, Qiang Zhang, Yuan Gao, Zhenyu Wu
Expert Review of Anticancer Therapy.2024; 24(6): 467. CrossRef
Neoadjuvant treatment of pancreatic ductal adenocarcinoma: Whom, when and how
Nebojsa Manojlovic, Goran Savic, Stevan Manojlovic
World Journal of Gastrointestinal Surgery.2024; 16(5): 1223. CrossRef
Case Study on Analysing the Early Disease Detection of Pancreatic Ductal Adenocarcinoma in Korean Association for Clinical Oncology
Sijithra Ponnarassery Chandran, N. Santhi
American Journal of Clinical Oncology.2024; 47(10): 475. CrossRef
Evaluating the benefits of adjuvant chemotherapy in patients with pancreatic cancer undergoing radical pancreatectomy after neoadjuvant therapy—a systematic review and meta-analysis
Jiahao Wu, Yike Zhang, Haodong Wang, Wenyi Guo, Chengqing Li, Yichen Yu, Han Liu, Feng Li, Lei Wang, Jianwei Xu
Frontiers in Oncology.2024;[Epub] CrossRef

5,609 View
164 Download
5 Web of Science
5 Crossref

Adjuvant Chemotherapy for Resected Ampulla of Vater Carcinoma: Retrospective Analysis of 646 Patients: Jwa Hoon Kim, Jae Ho Jeong, Baek-Yeol Ryoo, Kyu-pyo Kim, Heung-Moon Chang, Dongwook Oh, Tae Jun Song, Sang Soo Lee, Dong Wan Seo, Sung Koo Lee, Myung-Hwan Kim, Yejong Park, Jae Woo Kwon, Dae Wook Hwang, Jae Hoon Lee, Woohyung Lee, Song Cheol Kim, Changhoon Yoo, Ki Byung Song; Cancer Res Treat. 2021;53(2):424-435. Published online November 9, 2020; DOI: https://doi.org/10.4143/crt.2020.953

Abstract PDF Supplementary Material PubReader ePub

Purpose
This study evaluated the efficacy of adjuvant chemotherapy (AC) in patients with resected ampulla of Vater (AoV) carcinoma.
Materials and Methods
Data from 646 patients who underwent surgical resection at Asan Medical Center between 2000 and 2017 were retrospectively reviewed.
Results
The median age of the patients was 62 years, and 54.2% were male. Patients were classified into AC group (n=165, 25.5%) and no AC group (n=481, 74.5%). With a median follow-up duration of 88 months, in patients with stage I, II, III, median recurrence-free survival (RFS) was not reached, 44 months, and 15 months, respectively, and the median overall survival (OS) were not reached, 88 months and 35 months, respectively. Despite no statistical significance, RFS and OS were better in stage II patients with AC than in those without AC (median RFS, 151 months vs. 38 months; p=0.156 and median OS, 153 months vs. 74 months; p=0.299). In multivariate analysis for RFS and OS, TNM stage, R1 resection status, presence of lymphovascular invasion, and perineural invasion remained significant factors, whereas AC (hazard ratio [HR], 0.74; 95% confidence interval [CI], 0.54 to 1.00; p=0.052) was marginally related with RFS. After propensity score matching in only stage II/III patients, RFS and OS with AC were numerically longer than those without AC (HR, 0.80; 95% CI, 0.60 to 1.06; p=0.116 and HR, 0.77; 95% CI, 0.56 to 1.06; p=0.111).
Conclusion
AC with fluoropyrimidine did not improve survival of patients with resected AoV carcinoma. However, multivariate analysis with prognostic factors showed a marginally significant survival benefit with AC.

Citations

Citations to this article as recorded by

Survival benefit of concurrent chemoradiotherapy for advanced ampulla of Vater cancer
Chae Hwa Kwon, Hyung Il Seo, Dong Uk Kim, Sung Yong Han, Suk Kim, Nam Kyung Lee, Seung Baek Hong, Ji Hyun Ahn, Young Mok Park, Byeong Gwan Noh
World Journal of Clinical Cases.2024; 12(2): 267. CrossRef
Prognostic efficacy of lymph node parameters in resected ampullary adenocarcinoma based on long-term follow-up data after adjuvant treatment
Namyoung Park, In Rae Cho, Sang Hyub Lee, Joo Seong Kim, Jin Ho Choi, Min Woo Lee, Woo Hyun Paik, Kwang Ro Joo, Ji Kon Ryu, Yong-Tae Kim
World Journal of Surgical Oncology.2024;[Epub] CrossRef
Adjuvant Chemotherapy and Effect on Long-Term Survival in Ampullary Adenocarcinoma: A Multicenter Cohort Study
Dong Woo Shin, Jae Min Lee, Jong-chan Lee, Hee Seung Lee, Seung Bae Yoon, Dong Kee Jang, Joo Kyung Park, Min Kyu Jung, Yoon Suk Lee, Jin-Hyeok Hwang
Journal of the American College of Surgeons.2023; 237(3): 501. CrossRef
Role of adjuvant chemotherapy on recurrence and survival in patients with resected ampulla of Vater carcinoma
Se Jun Park, Kabsoo Shin, In-Ho Kim, Tae Ho Hong, Younghoon Kim, Myung-ah Lee
World Journal of Gastrointestinal Oncology.2023; 15(4): 677. CrossRef
Remission from the 5-Fu-Based Chemotherapy to Gemcitabine-Based Chemotherapy-Based on the Pathological Classification of Periampullary Carcinoma: A Case Report and Literature Review
Wei Hu, Zhiqing Duan, Yinuo Zhang, Jing Liu, Jing Bao, Ruqing Gao, Yajie Tang, Tiande Liu, Hu Xiong, Wen Li, Xiaowei Fu, Shousheng Liao, Lu Fang, Bo Liang
OncoTargets and Therapy.2022; Volume 15: 891. CrossRef

7,712 View
374 Download
7 Web of Science
5 Crossref

Spatial Distribution and Prognostic Implications of Tumor-Infiltrating FoxP3^- CD4⁺ T Cells in Biliary Tract Cancer: Hyung-Don Kim, Jwa Hoon Kim, Yeon-Mi Ryu, Danbee Kim, Sunmin Lee, Jaehoon Shin, Seung-Mo Hong, Ki-Hun Kim, Dong‐Hwan Jung, Gi‐Won Song, Dae Wook Hwang, Jae Hoon Lee, Ki Byung Song, Baek-Yeol Ryoo, Jae Ho Jeong, Kyu-pyo Kim, Sang-Yeob Kim, Changhoon Yoo; Cancer Res Treat. 2021;53(1):162-171. Published online August 31, 2020; DOI: https://doi.org/10.4143/crt.2020.704

Abstract PDF Supplementary Material PubReader ePub

Purpose
The clinical implications of tumor-infiltrating T cell subsets and their spatial distribution in biliary tract cancer (BTC) patients treated with gemcitabine plus cisplatin were investigated.
Materials and Methods
A total of 52 BTC patients treated with palliative gemcitabine plus cisplatin were included. Multiplexed immunohistochemistry was performed on tumor tissues, and immune infiltrates were separately analyzed for the stroma, tumor margin, and tumor core.
Results
The density of CD8⁺ T cells, FoxP3^- CD4⁺ helper T cells, and FoxP3⁺ CD4⁺ regulatory T cells was significantly higher in the tumor margin than in the stroma and tumor core. The density of LAG3- or TIM3-expressing CD8⁺ T cell and FoxP3^- CD4⁺ helper T cell infiltrates was also higher in the tumor margin. In extrahepatic cholangiocarcinoma, there was a higher density of T cell subsets in the tumor core and regulatory T cells in all regions. A high density of FoxP3^-CD4⁺ helper T cells in the tumor margin showed a trend toward better progression-free survival (PFS) (p=0.092) and significantly better overall survival (OS) (p=0.012). In multivariate analyses, a high density of FoxP3^- CD4⁺ helper T cells in the tumor margin was independently associated with favorable PFS and OS.
Conclusion
The tumor margin is the major site for the active infiltration of T cell subsets with higher levels of LAG3 and TIM3 expression in BTC. The density of tumor margin-infiltrating FoxP3^-CD4⁺ helper T cells may be associated with clinical outcomes in BTC patients treated with gemcitabine plus cisplatin.

Citations

Citations to this article as recorded by

Infiltrating T lymphocytes and tumor microenvironment within cholangiocarcinoma: immune heterogeneity, intercellular communication, immune checkpoints
Yunyan Dai, Chenyang Dong, Zhiming Wang, Yunpeng Zhou, Yi Wang, Yi Hao, Pinggui Chen, Chaojie Liang, Gaopeng Li
Frontiers in Immunology.2025;[Epub] CrossRef
Advancing biliary tract malignancy treatment: emerging frontiers in cell-based therapies
Jianyang Ao, Mingtai Hu, Jinghan Wang, Xiaoqing Jiang
Frontiers in Immunology.2025;[Epub] CrossRef
Research progress of T cells in cholangiocarcinoma
Zhiming Wang, Yunyan Dai, Yunpeng Zhou, Yi Wang, Pinggui Chen, Yaoxuan Li, Yunfei Zhang, Xiaocui Wang, Ying Hu, Haonan Li, Gaopeng Li, Yukai Jing
Frontiers in Immunology.2025;[Epub] CrossRef
Mapping of the T-cell Landscape of Biliary Tract Cancer Unravels Anatomic Subtype-Specific Heterogeneity
Jianhua Nie, Shuyuan Zhang, Ying Guo, Caiqi Liu, Jiaqi Shi, Haotian Wu, Ruisi Na, Yingjian Liang, Shan Yu, Fei Quan, Kun Liu, Mingwei Li, Meng Zhou, Ying Zhao, Xuehan Li, Shengnan Luo, Qian Zhang, Guangyu Wang, Yanqiao Zhang, Yuanfei Yao, Yun Xiao, Sheng
Cancer Research.2025; 85(4): 704. CrossRef
Deciphering the tumor immune microenvironment from a multidimensional omics perspective: insight into next-generation CAR-T cell immunotherapy and beyond
Zhaokai Zhou, Jiahui Wang, Jiaojiao Wang, Shuai Yang, Ruizhi Wang, Ge Zhang, Zhengrui Li, Run Shi, Zhan Wang, Qiong Lu
Molecular Cancer.2024;[Epub] CrossRef
Tumor-infiltrating T lymphocytes: A promising immunotherapeutic target for preventing immune escape in cholangiocarcinoma
Sijia Hua, Xinyi Gu, Hangbin Jin, Xiaofeng Zhang, Qiang Liu, Jianfeng Yang
Biomedicine & Pharmacotherapy.2024; 177: 117080. CrossRef
Focusing on the Immune Cells: Recent Advances in Immunotherapy for Biliary Tract Cancer
Luohang Ni, Jianing Xu, Quanpeng Li, Xianxiu Ge, Fei Wang, Xueting Deng, Lin Miao
Cancer Management and Research.2024; Volume 16: 941. CrossRef
Artificial Intelligence-Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as a Potential Biomarker for Immune Checkpoint Inhibitors in Patients with Biliary Tract Cancer
Yeong Hak Bang, Choong-kun Lee, Kyunghye Bang, Hyung-Don Kim, Kyu-pyo Kim, Jae Ho Jeong, Inkeun Park, Baek-Yeol Ryoo, Dong Ki Lee, Hye Jin Choi, Taek Chung, Seung Hyuck Jeon, Eui-Cheol Shin, Chiyoon Oum, Seulki Kim, Yoojoo Lim, Gahee Park, Chang Ho Ahn, T
Clinical Cancer Research.2024; 30(20): 4635. CrossRef
Prognostic value of tumor-infiltrating lymphocytes in distal extrahepatic bile duct carcinoma
S.-Y. Jun, S. An, S.-M. Hong, J.-Y. Kim, K.-P. Kim
ESMO Open.2024; 9(11): 103969. CrossRef
Modulation of FOXP3 Gene Expression in OVCAR3 Cells Following Rosmarinic Acid and Doxorubicin Exposure
Veysel Toprak, İlhan Özdemir, Şamil Öztürk, Orhan Yanar, Yusuf Ziya Kizildemir, Mehmet Cudi Tuncer
Pharmaceuticals.2024; 17(12): 1606. CrossRef
The Immunomodulatory Role of Vitamin D in Regulating the Th17/Treg Balance and Epithelial–Mesenchymal Transition: A Hypothesis for Gallbladder Cancer
Ricardo Cartes-Velásquez, Agustín Vera, Rodrigo Torres-Quevedo, Jorge Medrano-Díaz, Andy Pérez, Camila Muñoz, Hernán Carrillo-Bestagno, Estefanía Nova-Lamperti
Nutrients.2024; 16(23): 4134. CrossRef
Tumor immune microenvironment and the current immunotherapy of cholangiocarcinoma (Review)
Siqi Yang, Ruiqi Zou, Yushi Dai, Yafei Hu, Fuyu Li, Haijie Hu
International Journal of Oncology.2023;[Epub] CrossRef
Therapeutic significance of tumor microenvironment in cholangiocarcinoma: focus on tumor-infiltrating T lymphocytes
Chaoqun Li, Lei Bie, Muhua Chen, Jieer Ying
Exploration of Targeted Anti-tumor Therapy.2023; 4(6): 1310. CrossRef
Dynamic increase of M2 macrophages is associated with disease progression of colorectal cancers following cetuximab-based treatment
Hyung-Don Kim, Sun Young Kim, Jihun Kim, Jeong Eun Kim, Yong Sang Hong, Buhm Han, Eunyoung Tak, Yeon-Mi Ryu, Sang-Yeob Kim, Tae Won Kim
Scientific Reports.2022;[Epub] CrossRef
Up-to-Date Pathologic Classification and Molecular Characteristics of Intrahepatic Cholangiocarcinoma
Taek Chung, Young Nyun Park
Frontiers in Medicine.2022;[Epub] CrossRef
The role of tumor-infiltrating lymphocytes in cholangiocarcinoma
Dong Liu, Lara Rosaline Heij, Zoltan Czigany, Edgar Dahl, Sven Arke Lang, Tom Florian Ulmer, Tom Luedde, Ulf Peter Neumann, Jan Bednarsch
Journal of Experimental & Clinical Cancer Research.2022;[Epub] CrossRef
Clinical implications of the tumor microenvironment using multiplexed immunohistochemistry in patients with advanced or metastatic renal cell carcinoma treated with nivolumab plus ipilimumab
Jwa Hoon Kim, Gi Hwan Kim, Yeon-Mi Ryu, Sang-Yeob Kim, Hyung-Don Kim, Shin Kyo Yoon, Yong Mee Cho, Jae Lyun Lee
Frontiers in Oncology.2022;[Epub] CrossRef
Spatial architecture of the immune microenvironment orchestrates tumor immunity and therapeutic response
Tong Fu, Lei-Jie Dai, Song-Yang Wu, Yi Xiao, Ding Ma, Yi-Zhou Jiang, Zhi-Ming Shao
Journal of Hematology & Oncology.2021;[Epub] CrossRef

8,381 View
236 Download
19 Web of Science
18 Crossref

Prognostic Predictability of American Joint Committee on Cancer 8th Staging System for Perihilar Cholangiocarcinoma: Limited Improvement Compared with the 7th Staging System: Jong Woo Lee, Jae Hoon Lee, Yejong Park, Woohyung Lee, Jaewoo Kwon, Ki Byung Song, Dae Wook Hwang, Song Cheol Kim; Cancer Res Treat. 2020;52(3):886-895. Published online March 12, 2020; DOI: https://doi.org/10.4143/crt.2020.023

Abstract PDF PubReader ePub

Purpose
This study was conducted to evaluate the prognostic values of the 7th and 8th American Joint Committee on Cancer (AJCC) staging systems for patients with resected perihilar cholangiocarcinoma (PHCC).
Materials and Methods
A total of 348 patients who underwent major hepatectomy for PHCC between 2008 and 2015 were identified from a single center. Overall survival (OS) was estimated using the Kaplan-Meier method and compared across stage groups with the log-rank test. The concordance index was used to evaluate the prognostic predictability of the 8th AJCC staging system compared with that of the 7th.
Results
In the 8th edition, the stratification of each group of T classification improved compared to that in the 7th, as the survival rate of T4 decreased (T2, 31.2%; T3, 13.9%; T4, 15.1%; T1- T2, p=0.260; T2-T3, p=0.001; T3-T4, p=0.996). Both editions showed significant survival differences between each N category, except between N1 and N2 (p=0.063) in 7th edition. Differences of point estimates between the 8th and 7th T and N classification and overall stages were +0.028, +0.006, and +0.039, respectively (T, p=0.005; N, p=0.115; overall stage, p=0.005). In multivariable analysis, posthepatectomy liver failure, T category, N category, distant metastasis, histologic differentiation, intraoperative transfusion, and resection margin status were associated with OS.
Conclusion
The prognostic predictability of 8th AJCC staging for PHCC improved slightly, with statistical significance, compared to the 7th edition, but its overall performance is still unsatisfactory.

Citations

Citations to this article as recorded by

Postoperative factors predicting outcomes in patients with Perihilar cholangiocarcinoma undergoing curative resection—a 10-year single-center experience
Hasan Ahmad Al-Saffar, Nicolai Schultz, Peter Nørrgaard Larsen, Eva Fallentin, Gro Linno Willemoe, Diana Elena Renteria Ramirez, Lucas Alexander Knøfler, Hans-Christian Pommergaard
Scandinavian Journal of Gastroenterology.2025; 60(1): 73. CrossRef
The preoperative scoring system combining neutrophil/lymphocyte ratio and CA19-9 predicts the long-term prognosis of intrahepatic cholangiocarcinoma patients undergoing curative liver resection
Shilei Bai, Xiaodong Shi, Yizhe Dai, Huifeng Wang, Yong Xia, Jian Liu, Kui Wang
BMC Cancer.2024;[Epub] CrossRef
Preoperative factors predicting outcomes in patients with suspected perihilar cholangiocarcinoma referred for curative resection— a single-center 10-year experience
HA Al-Saffar, PN Larsen, N Schultz, TS Kristensen, DE Renteria, LA Knøfler, HC Pommergaard
Langenbeck's Archives of Surgery.2024;[Epub] CrossRef
Evaluation of Four Lymph Node Classifications for the Prediction of Survival in Hilar Cholangiocarcinoma
Zhi-Peng Liu, Qing-Yi Zhang, Wei-Yue Chen, Yu-Yan Huang, Yan-Qi Zhang, Yi Gong, Yan Jiang, Jie Bai, Zhi-Yu Chen, Hai-Su Dai
Journal of Gastrointestinal Surgery.2022; 26(5): 1030. CrossRef
Impact of Positive Lymph Nodes and Resection Margin Status on the Overall Survival of Patients with Resected Perihilar Cholangiocarcinoma: The ENSCCA Registry
Lynn E. Nooijen, Jesus M. Banales, Marieke T. de Boer, Chiara Braconi, Trine Folseraas, Alejandro Forner, Waclaw Holowko, Frederik J. H. Hoogwater, Heinz-Josef Klümpen, Bas Groot Koerkamp, Angela Lamarca, Adelaida La Casta, Flora López-López, Laura Izquie
Cancers.2022; 14(10): 2389. CrossRef
Modification of the eighth AJCC/UICC staging system for perihilar cholangiocarcinoma: An alternative pathological staging system from cholangiocarcinoma-prevalent Northeast Thailand
Chaiwat Aphivatanasiri, Prakasit Sa-Ngiamwibool, Sakkarn Sangkhamanon, Piyapharom Intarawichian, Waritta Kunprom, Malinee Thanee, Piya Prajumwongs, Narong Khuntikeo, Attapol Titapun, Apiwat Jareanrat, Vasin Thanasukarn, Tharatip Srisuk, Vor Luvira, Kulyad
Frontiers in Medicine.2022;[Epub] CrossRef
Vascular invasion and lymph node metastasis mediate the effect of CA242 on prognosis in hilar cholangiocarcinoma patients after radical resection
Gang Heng, Benqi Huang, Yanbing Shen, Dan wang, Zhen Lan, Yuxuan Yao, Jianxin Zhang, Jiankun Jia, Chengcheng Zhang
Frontiers in Oncology.2022;[Epub] CrossRef
Development and validation of preoperative magnetic resonance imaging-based survival predictive nomograms for patients with perihilar cholangiocarcinoma after radical resection: A pilot study
Jian Zhao, Wei Zhang, Cheng-Lin Fan, Jun Zhang, Fang Yuan, Si-Yun Liu, Fu-Yu Li, Bin Song
European Journal of Radiology.2021; 138: 109631. CrossRef
A Novel Nomogram Based on Log Odds of Metastatic Lymph Nodes to Predict Overall Survival in Patients With Perihilar Cholangiocarcinoma After Surgery
Wenbo Zou, Chunyu Zhu, Zizheng Wang, Xianglong Tan, Chenggang Li, Zhiming Zhao, Minggen Hu, Rong Liu
Frontiers in Oncology.2021;[Epub] CrossRef
Prognostic Relevance of the Eighth Edition of TNM Classification for Resected Perihilar Cholangiocarcinoma
Hans-Michael Hau, Felix Meyer, Nora Jahn, Sebastian Rademacher, Robert Sucher, Daniel Seehofer
Journal of Clinical Medicine.2020; 9(10): 3152. CrossRef

7,573 View
166 Download
14 Web of Science
10 Crossref

Efficacy and Safety of Pembrolizumab in Patients with Refractory Advanced Biliary Tract Cancer: Tumor Proportion Score as a Potential Biomarker for Response: Junho Kang, Jae Ho Jeong, Hee-Sang Hwang, Sang Soo Lee, Do Hyun Park, Dong Wook Oh, Tae Jun Song, Ki-Hun Kim, Shin Hwang, Dae Wook Hwang, Song Cheol Kim, Jin-hong Park, Seung-Mo Hong, Kyu-pyo Kim, Baek-Yeol Ryoo, Changhoon Yoo; Cancer Res Treat. 2020;52(2):594-603. Published online December 18, 2019; DOI: https://doi.org/10.4143/crt.2019.493

Abstract PDF PubReader ePub

Purpose
The current standard chemotherapy for advanced biliary tract cancer (BTC) has limited benefit, and novel therapies need to be investigated.
Materials and Methods
In this prospective cohort study, programmed death ligand-1 (PD-L1)–positive BTC patients who progressed on first-line gemcitabine plus cisplatin were enrolled. Pembrolizumab 200 mg was administered intravenously every 3 weeks.
Results
Between May 2018 and February 2019, 40 patients were enrolled. Pembrolizumab was given as second-line (47.5%) or ≥ third-line therapy (52.5%). The objective response rate was 10% and 12.5% by Response Evaluation Criteria in Solid Tumor (RECIST) v1.1 and immune- modified RECIST (imRECIST) and median duration of response was 6.3 months. Among patients with progressive disease as best response, one patient (1/20, 5.0%) achieved complete response subsequently. The median progression-free survival (PFS) and overall survival (OS) were 1.5 months (95% confidence interval [CI], 0.0 to 3.0) and 4.3 months (95% CI, 3.5 to 5.1), respectively, and objective response per imRECIST was significantly associated with PFS (p < 0.001) and OS (p=0.001). Tumor proportion score ≥ 50% was significantly associated with higher response rates including the response after pseudoprogression (vs. < 50%; 37.5% vs. 6.5%; p=0.049).
Conclusion
Pembrolizumab showed modest anti-tumor activity in heavily pretreated PD-L1–positive BTC patients. In patients who showed objective response, durable response could be achieved.

Citations

Citations to this article as recorded by

Camrelizumab combined with gemcitabine and apatinib in treating advanced PD‐L1‐positive biliary tract cancers
Yitong Tian, Changxian Li, Ke Jin, Ling Ma, Jiaguang Zhang, Xinyi Zhang, Wei You, Haoyang Shen, Yuting Ding, Hao Qian, Xiangcheng Li, Xiaofeng Chen
Cancer Science.2025; 116(1): 204. CrossRef
Ex vivo liver resection and auto-transplantation and special systemic therapy in perihilar cholangiocarcinoma treatment
Konstantin Y Tchilikidi
World Journal of Gastrointestinal Surgery.2024; 16(3): 635. CrossRef
The predictive value of PD-L1 expression in response to anti-PD-1/PD-L1 therapy for biliary tract cancer: a systematic review and meta-analysis
Seung Bae Yoon, Sang Myung Woo, Jung Won Chun, Dong Uk Kim, Jaihwan Kim, Joo Kyung Park, Hoonsub So, Moon Jae Chung, In Rae Cho, Jun Heo
Frontiers in Immunology.2024;[Epub] CrossRef
Unveiling the promise of PD1/PD-L1: A new dawn in immunotherapy for cholangiocarcinoma
Fei Chen, Jian Sheng, Xiaoping Li, Zhaofeng Gao, Siqi Zhao, Lingyu Hu, Minjie Chen, Jianguo Fei, Zhengwei Song
Biomedicine & Pharmacotherapy.2024; 175: 116659. CrossRef
Clinical outcomes of immune checkpoint inhibitor combined with other targeted or immunological therapy regimens for the treatment of advanced bile tract cancer: a systematic review and meta-analysis
Jianpeng Zhou, Jia Li, Zhongqi Fan, Guoyue Lv, Guangyi Wang
Frontiers in Immunology.2024;[Epub] CrossRef
The Immune Landscape and Its Potential for Immunotherapy in Advanced Biliary Tract Cancer
Andry Santoso, Iris Levink, Rille Pihlak, Ian Chau
Current Oncology.2024; 32(1): 24. CrossRef
Emerging pharmaceutical therapies for targeting cholangiocarcinoma microenvironment and chemokine pathways
ARMAND N. YAZDANI, MICHAELA PLETSCH, ABRAHAM CHORBAJIAN, DAVID ZITSER, VIKRANT RAI
BIOCELL.2024; 48(12): 1683. CrossRef
Anti-PD-1-based immunotherapy plus lenvatinib to treat advanced gallbladder cancer in the elderly: a case series and review of current literature
Lantian Wang, Kezhong Tang, Xiawei Li, Wenjie Lu
Journal of Cancer Research and Clinical Oncology.2023; 149(3): 941. CrossRef
A prospective multicenter phase II study of FOLFIRINOX as a first-line treatment for patients with advanced and recurrent biliary tract cancer
Naminatsu Takahara, Yousuke Nakai, Hiroyuki Isayama, Takashi Sasaki, Yuji Morine, Kazuo Watanabe, Makoto Ueno, Tatsuya Ioka, Masashi Kanai, Shunsuke Kondo, Naohiro Okano, Kazuhiko Koike
Investigational New Drugs.2023; 41(1): 76. CrossRef
Revisiting targeted therapy and immunotherapy for advanced cholangiocarcinoma
Jiajia Du, Xing Lv, Zunyi Zhang, Zhiyong Huang, Erlei Zhang
Frontiers in Immunology.2023;[Epub] CrossRef
Clinical outcomes of immune checkpoint inhibitors in unresectable or metastatic combined hepatocellular–cholangiocarcinoma
Yoon Jung Jang, Eo Jin Kim, Hyung-Don Kim, Kyu-Pyo Kim, Min-Hee Ryu, Sook Ryun Park, Won-Mook Choi, Danbi Lee, Jonggi Choi, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim, Han Chu Lee, Baek-Yeol Ryoo, Changhoon Yoo
Journal of Cancer Research and Clinical Oncology.2023; 149(10): 7547. CrossRef
Precision Medicine and Immunotherapy Have Arrived for Cholangiocarcinoma: An Overview of Recent Approvals and Ongoing Clinical Trials
Thomas B. Karasic, Jennifer R. Eads, Lipika Goyal
JCO Precision Oncology.2023;[Epub] CrossRef
Moving Beyond Single-Agent Checkpoint Inhibition in Biliary Tract Cancers: What is the Next Frontier?
Pedro Luiz Serrano Uson Junior, Tanios Bekaii-Saab
Immunotherapy.2023; 15(7): 531. CrossRef
Chemo-Free Treatment Using Anti-PD-1 Antibodies with Lenvatinib in Unresectable Gallbladder Cancer: PD-L1 May Be a Potential Biomarker for a Better Outcome
Tiantian Wu, Changsheng Pu, Xianjia Wu, Qiang Wang, Keming Zhang
Diagnostics.2023; 13(11): 1833. CrossRef
Lacking Immunotherapy Biomarkers for Biliary Tract Cancer: A Comprehensive Systematic Literature Review and Meta-Analysis
Giorgio Frega, Fernando P. Cossio, Jesus M. Banales, Vincenzo Cardinale, Rocio I. R. Macias, Chiara Braconi, Angela Lamarca
Cells.2023; 12(16): 2098. CrossRef
Comparison of Efficacy and Safety of Anti-Programmed Cell Death-1 Antibody Plus Lenvatinib and Chemotherapy as First-Line Therapy for Patients with Stage IV Gallbladder Cancer: A Real-World Study in a Chinese Population
Tiantian Wu, Changsheng Pu, Qiang Wang, Keming Zhang
Biomedicines.2023; 11(11): 2933. CrossRef
The Expression of Programmed Death-Ligand 1 on Immune Cells Is Related to a Better Prognosis in Biliary Tract Cancer
Sung Chan Kwon, Seungmin Bang, Young Nyun Park, Ji Hoon Park, So Jeong Kim, Jung Hyun Jo, Moon Jae Chung, Jeong Youp Park, Seung Woo Park, Si Young Song, Eunhyang Park, Hee Seung Lee
Gut and Liver.2023; 17(6): 933. CrossRef
Equipoise, drug development, and biliary cancer
Tristan Y. Lee, Susan E. Bates, Ghassan K. Abou‐Alfa
Cancer.2022; 128(5): 944. CrossRef
Novel and emerging targets for cholangiocarcinoma progression: therapeutic implications
Lionel A. Kankeu Fonkoua, Pedro Luiz Serrano Uson Junior, Kabir Mody, Amit Mahipal, Mitesh J. Borad, Lewis R. Roberts
Expert Opinion on Therapeutic Targets.2022; 26(1): 79. CrossRef
Penpulimab, an anti-PD1 IgG1 antibody in the treatment of advanced or metastatic upper gastrointestinal cancers
Yulong Zheng, Anna Rachelle Austria Mislang, Jermaine Coward, Rasha Cosman, Adam Cooper, Craig Underhill, Jianqing Zhu, Jianping Xiong, Ou Jiang, Hong Wang, Yanru Xie, Yuefen Zhou, Xiaoping Jin, Baiyong Li, Zhongmin Maxwell Wang, Kon Yew Kwek, Dennis Xia,
Cancer Immunology, Immunotherapy.2022; 71(10): 2371. CrossRef
Efficacy and Safety of Anti-PD1/PDL1 in Advanced Biliary Tract Cancer: A Systematic Review and Meta-Analysis
Qi Jiang, Jinsheng Huang, Bei Zhang, Xujia Li, Xiuxing Chen, Bokang Cui, Shengping Li, Guifang Guo
Frontiers in Immunology.2022;[Epub] CrossRef
Real-world outcomes of patients with advanced intrahepatic cholangiocarcinoma treated with programmed cell death protein-1-targeted immunotherapy
Min Deng, Shaohua Li, Qiaoxuan Wang, Rongce Zhao, Jingwen Zou, Wenping Lin, Jie Mei, Wei Wei, Rongping Guo
Annals of Medicine.2022; 54(1): 803. CrossRef
Immune cell atlas of cholangiocarcinomas reveals distinct tumor microenvironments and associated prognoses
Tao Xia, Keyu Li, Nan Niu, Yingkuan Shao, Ding Ding, Dwayne L. Thomas, Hao Jing, Kenji Fujiwara, Haijie Hu, Arsen Osipov, Chunhui Yuan, Christopher L. Wolfgang, Elizabeth D. Thompson, Robert A. Anders, Jin He, Yiping Mou, Adrian G. Murphy, Lei Zheng
Journal of Hematology & Oncology.2022;[Epub] CrossRef
Targeted Therapies for Perihilar Cholangiocarcinoma
Simon Gray, Angela Lamarca, Julien Edeline, Heinz-Josef Klümpen, Richard A. Hubner, Mairéad G. McNamara, Juan W. Valle
Cancers.2022; 14(7): 1789. CrossRef
Novel Palliative Chemotherapy for Cholangiocarcinoma
Jung Won Jung, Sang Myung Woo
The Korean Journal of Pancreas and Biliary Tract.2022; 27(2): 90. CrossRef
Advances in the systemic treatment of therapeutic approaches in biliary tract cancer
O. Mirallas, D. López-Valbuena, D. García-Illescas, C. Fabregat-Franco, H. Verdaguer, J. Tabernero, T. Macarulla
ESMO Open.2022; 7(3): 100503. CrossRef
Aging and biliary tract cancers: Epidemiology, molecular biology, and clinical practice
Xiaoling Weng, Xiaoling Song, Rong Shao, Fatao Liu, Yingbin Liu
Aging and Cancer.2022; 3(2): 95. CrossRef
Efficacy and Safety of Drug-Eluting Beads Transarterial Chemoembolization Combining Immune Checkpoint Inhibitors in Unresectable Intrahepatic Cholangiocarcinoma: A Propensity Score Matching Analysis
Xue-Gang Yang, Yan-Yuan Sun, De-Shan Li, Guo-Hui Xu, Xiao-Qi Huang
Frontiers in Immunology.2022;[Epub] CrossRef
Lenvatinib Plus Programmed Cell Death Protein-1 Inhibitor Beyond First-Line Systemic Therapy in Refractory Advanced Biliary Tract Cancer: A Real-World Retrospective Study in China
Changying Shi, Yulong Li, Cheng Yang, Liang Qiao, Liukang Tang, Yuting Zheng, Xue Chen, Youwen Qian, Jiamei Yang, Dong Wu, Feng Xie
Frontiers in Immunology.2022;[Epub] CrossRef
Immunotherapy in biliary tract cancers: Current evidence and future perspectives
Pedro Luiz Serrano Uson Junior, Raphael LC Araujo
World Journal of Gastrointestinal Oncology.2022; 14(8): 1446. CrossRef
Immune Checkpoint Inhibitors for Advanced Biliary Tract Cancer
Hossein Taghizadeh, Gerald W. Prager
Current Cancer Drug Targets.2022; 22(8): 639. CrossRef
Safety and Efficacy of Allogeneic Natural Killer Cells in Combination with Pembrolizumab in Patients with Chemotherapy-Refractory Biliary Tract Cancer: A Multicenter Open-Label Phase 1/2a Trial
Galam Leem, Sung-Ill Jang, Jae-Hee Cho, Jung Hyun Jo, Hee Seung Lee, Moon Jae Chung, Jeong Youp Park, Seungmin Bang, Da-Kyung Yoo, Hyo-Cheon Cheon, Jae-Eun Kim, Kyeong-Pill Lim, In-Hye Jung, Jung-Min Im, Yong-Yoon Chung, Seung Woo Park
Cancers.2022; 14(17): 4229. CrossRef
Prognostic Factors in Patients Treated with Pembrolizumab as a Second-Line Treatment for Advanced Biliary Tract Cancer
Chan Su Park, Min Je Sung, So Jeong Kim, Jung Hyun Jo, Hee Seung Lee, Moon Jae Chung, Seungmin Bang, Seung Woo Park, Si Young Song, Jeong Youp Park
Cancers.2022; 14(17): 4323. CrossRef
The Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Based on FOLFIRI for Advanced Intrahepatic Cholangiocarcinoma as Second-Line and Successive Treatment: A Real-World Study
Peixin Huang, Xiaoyong Huang, Yingting Zhou, Guohuan Yang, Qiman Sun, Guoming Shi, Yi Chen, Quirino Lai
Canadian Journal of Gastroenterology and Hepatology.2022; 2022: 1. CrossRef
PD-1 inhibitors plus nab-paclitaxel-containing chemotherapy for advanced gallbladder cancer in a second-line setting: A retrospective analysis of a case series
Sirui Tan, Jing Yu, Qiyue Huang, Nan Zhou, Hongfeng Gou
Frontiers in Oncology.2022;[Epub] CrossRef
Treating Biliary Tract Cancers: New Targets and Therapies
Joseph Ho, Constance Fiocco, Kristen Spencer
Drugs.2022; 82(17): 1629. CrossRef
Immunotherapies in clinical development for biliary tract cancer
Arndt Vogel, Melanie Bathon, Anna Saborowski
Expert Opinion on Investigational Drugs.2021; 30(4): 351. CrossRef
Spatial Distribution and Prognostic Implications of Tumor-Infiltrating FoxP3- CD4+ T Cells in Biliary Tract Cancer
Hyung-Don Kim, Jwa Hoon Kim, Yeon-Mi Ryu, Danbee Kim, Sunmin Lee, Jaehoon Shin, Seung-Mo Hong, Ki-Hun Kim, Dong‐Hwan Jung, Gi‐Won Song, Dae Wook Hwang, Jae Hoon Lee, Ki Byung Song, Baek-Yeol Ryoo, Jae Ho Jeong, Kyu-pyo Kim, Sang-Yeob Kim, Changhoon Yoo
Cancer Research and Treatment.2021; 53(1): 162. CrossRef
Clinically significant genomic alterations in the Chinese and Western patients with intrahepatic cholangiocarcinoma
Shifeng Xu, Yuan Guo, Yanwu Zeng, Zhijian Song, Xiaodan Zhu, Ning Fan, Zhilei Zhang, Guibing Ren, Yunjin Zang, Wei Rao
BMC Cancer.2021;[Epub] CrossRef
Successful pembrolizumab treatment of microsatellite instability‐high intrahepatic cholangiocarcinoma: A case report
Yuki Ikeda, Michihiro Ono, Ginji Ohmori, Saki Ameda, Michiko Yamada, Tomoyuki Abe, Shigeyuki Fujii, Miri Fujita, Masahiro Maeda
Clinical Case Reports.2021; 9(4): 2259. CrossRef
Horizons on the Therapy of Biliary Tract Cancers: A State-of-the-art Review
Ran Xue, Rong Li, Jianxin Wang, Weiping Tong, Jianyu Hao
Journal of Clinical and Translational Hepatology.2021; 000(000): 000. CrossRef
An Assessment of Combination of the Camrelizumab With Chemotherapy in Metastatic Biliary Tract Cancers
Yi Yu, Shanshan Huang, Jun Chen, Feng Yu, Lin Zhang, Xiaojun Xiang, Jun Deng, Ziling Fang, Junhe Li, Jianping Xiong
Cancer Control.2021;[Epub] CrossRef
Gastrointestinal cancer treatment with immune checkpoint inhibitors
Jin Won Kim
Journal of the Korean Medical Association.2021; 64(5): 342. CrossRef
Phase 1b study of pegylated arginine deiminase (ADI-PEG 20) plus Pembrolizumab in advanced solid cancers
Kwang-Yu Chang, Nai-Jung Chiang, Shang-Yin Wu, Chia-Jui Yen, Shang-Hung Chen, Yu-Min Yeh, Chien-Feng Li, Xiaoxing Feng, Katherine Wu, Amanda Johnston, John S. Bomalaski, Bor-Wen Wu, Jianjun Gao, Sumit K. Subudhi, Ahmed O. Kaseb, Jorge M. Blando, Shalini S
OncoImmunology.2021;[Epub] CrossRef
A randomised phase II study of oxaliplatin/5-FU (mFOLFOX) versus irinotecan/5-FU (mFOLFIRI) chemotherapy in locally advanced or metastatic biliary tract cancer refractory to first-line gemcitabine/cisplatin chemotherapy
In Sil Choi, Ki Hwan Kim, Ju Hyun Lee, Koung Jin Suh, Ji-Won Kim, Jin Hyun Park, Yu Jung Kim, Jin-Soo Kim, Jee Hyun Kim, Jin Won Kim
European Journal of Cancer.2021; 154: 288. CrossRef
IMbrave 151: a randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer
Stephen P. Hack, Wendy Verret, Sohail Mulla, Bo Liu, Yulei Wang, Teresa Macarulla, Zhenggang Ren, Anthony B. El-Khoueiry, Andrew X. Zhu
Therapeutic Advances in Medical Oncology.2021;[Epub] CrossRef
Case Report: Response With Immunotherapy in a Patient With Mixed Neuroendocrine Non-Neuroendocrine Neoplasms of the Gallbladder
Chao Liu, Xiangwei Hua, Zhen Yang, Yuan Guo, Liqun Wu, Jinzhen Cai, Ling Li, Yaxuan Zhang, Ning Fan
Frontiers in Oncology.2021;[Epub] CrossRef
Durable Response of Immune Checkpoint Inhibitor after Failure of Gemcitabine-based Chemotherapy for a Patient with Metastatic Biliary Tract Cancer
Chien-Huai Chuang, Chiun Hsu
Journal of Cancer Research and Practice.2021; 8(4): 152. CrossRef
Efficacy and Safety of Pembrolizumab for Gemcitabine/Cisplatin-Refractory Biliary Tract Cancer: A Multicenter Retrospective Study
Sang Hoon Lee, Hee Seung Lee, Sang Hyub Lee, Sang Myung Woo, Dong Uk Kim, Seungmin Bang
Journal of Clinical Medicine.2020; 9(6): 1769. CrossRef
Systemic treatment of advanced or recurrent biliary tract cancer
Wei Zhang, Hongyuan Zhou, Yingying Wang, Zewu Zhang, Guangtai Cao, Tianqiang Song, Ti Zhang, Qiang Li
BioScience Trends.2020; 14(5): 328. CrossRef
Overview of current targeted therapy in gallbladder cancer
Xiaoling Song, Yunping Hu, Yongsheng Li, Rong Shao, Fatao Liu, Yingbin Liu
Signal Transduction and Targeted Therapy.2020;[Epub] CrossRef

14,316 View
412 Download
53 Web of Science
51 Crossref

Validation of the 8th Edition of the American Joint Committee on Cancer Staging System for Gallbladder Cancer and Implications for the Follow-up of Patients without Node Dissection: You-Na Sung, Minjeong Song, Jae Hoon Lee, Ki Byung Song, Dae Wook Hwang, Chul-Soo Ahn, Shin Hwang, Seung-Mo Hong; Cancer Res Treat. 2020;52(2):455-468. Published online October 17, 2019; DOI: https://doi.org/10.4143/crt.2019.271

Abstract PDF PubReader ePub

Purpose
The 8th edition of gallbladder cancer staging in the American Joint Committee on Cancer (AJCC) staging system changed the T and N categories.
Materials and Methods
In order to validate the new staging system, a total of 348 surgically resected gallbladder cancers were grouped based on the 8th edition of the T and N categories and compared with patients’ survival.
Results
Significant differences were noted between T1b-T2a (p=0.003) and T2b-T3 (p < 0.001) tumors, but not between Tis-T1a, T1a-T1b, and T2a-T2b tumors. However, significant survival differences were observed both by the overall and pair-wise (T1-T2, T2-T3) comparisons (all, p < 0.001) without dividing T1/T2 subcategories. When cases with ≥ 6 examined lymph nodes were evaluated, significant survival differences were observed among the entire comparison (p < 0.001) and pair-wise comparisons of N0-N1 (p=0.001) and N1-N2 (p=0.039) lesions. When cases without nodal dissection (NX) were additionally compared, significant survival differences were observed between patients with N0-NX (p=0.001) and NX-N1 (p < 0.001) lesions.
Conclusion
The T category in the 8th edition of the AJCC staging system did not completely stratify the prognosis of patients with gallbladder cancer. Modification by eliminating T subcategories can better stratify the prognosis. In contrast, the N category clearly determines patients’ survival with ≥ 6 examined lymph nodes. The survival time in patients of gallbladder cancers without nodal dissection is between N0 and N1 cases. Therefore, close postoperative followed up is recommended for those patients.

Citations

Citations to this article as recorded by

Comparison of Prognostic Performance of 8th and 7th Edition of AJCC Staging System for Patients With Gallbladder Cancer Undergoing Curative Intent Surgery
Sameer Gupta, Abhishek Verma, Arun Chaturvedi, Puneet Prakash, Vijay Kumar, Sanjeev Misra, Naseem Akhtar, Shiv Rajan, Preeti Agarwal, Lynette Smith, Makayla Schissel, Chandrakanth Are
Journal of Surgical Oncology.2025; 131(2): 220. CrossRef
T1b gallbladder cancer: is extended resection warranted?
Montserrat Chavez, Xabier de Aretxabala, Hector Losada, Norberto Portillo, Felipe Castillo, Luis Bustos, Ivan Roa
HPB.2025; 27(4): 523. CrossRef
TEAD4 promoted proliferation and metastasis of gallbladder cancer by regulation of TMPRSS4
Conglin Lin, Congren Wang, Mingzhu Li, Zhibing Cai
Clinical & Experimental Metastasis.2025;[Epub] CrossRef
Stage Evaluation of Cystic Duct Cancer
Yeseul Kim, You-Na Sung, Haesung Jung, Kyung Jin Lee, Daegwang Yoo, Sun-Young Jun, HyungJun Cho, Shin Hwang, Woohyung Lee, Seung-Mo Hong
Cancer Research and Treatment.2025; 57(2): 528. CrossRef
Intramucosal Extent as a Marker for Advanced Disease and Survival in Gallbladder Adenocarcinoma
Robert Naples, Breanna C. Perlmutter, Haiyan Lu, Daniela Allende, Chao Tu, Asif Hitawala, Pravallika Chadalavada, Vinay Padbidri, Abdo Haddad, Robert Simon, R. Matthew Walsh, Toms Augustin
The American Surgeon™.2024; 90(6): 1133. CrossRef
DNMT3A Cooperates with YAP/TAZ to Drive Gallbladder Cancer Metastasis
Sunwang Xu, Zhiqing Yuan, Cen Jiang, Wei Chen, Qiwei Li, Tao Chen
Advanced Science.2024;[Epub] CrossRef
Outcomes of patients with gallbladder cancer presenting with acute cholecystitis
Nunzio F Franco, Ngee-Soon Lau, Wai M Liu, Aadil Rahim, Mitali Fadia, Yu Jo Chua, Ankit Jain, Desmond Yip, Sivakumar Gananadha
Langenbeck's Archives of Surgery.2024;[Epub] CrossRef
Case and Management Considerations of Low‐Grade Cystic Duct Stump Dysplasia after Laparoscopic Cholecystectomy
Claire Ufongene, Saran Kunaprayoon, Juan Mestre, Dimitrios Mantas
Case Reports in Surgery.2024;[Epub] CrossRef
Gallbladder Cancer
Giacomo C. Waller, Umut Sarpel
Surgical Clinics of North America.2024; 104(6): 1263. CrossRef
Robotic resection for gallbladder cancer: Superior lymphadenectomy does not equal better survival
Michela Fabricius, Amika Ekanem, Allison N. Martin
Surgery.2024; 176(4): 1016. CrossRef
Prognostic utility of the modified albumin-bilirubin score among patients undergoing curative-intent surgery for gallbladder cancer
Odysseas P. Chatzipanagiotou, Diamantis I. Tsilimigras, Giovanni Catalano, Andrea Ruzzenente, Federico Aucejo, Hugo P. Marques, Vincent Lam, Nazim Bhimani, Shishir K. Maithel, Itaru Endo, Minoru Kitago, Timothy M. Pawlik
Journal of Gastrointestinal Surgery.2024; 28(12): 2075. CrossRef
A Single-Center Analysis of Patient Characteristics and Overall Survival in Patients with Resectable Gallbladder Cancer
N. Begüm Öztürk, Artem Dadamyan, Laith H. Jamil
Healthcare.2024; 12(20): 2091. CrossRef
Survival Predictors of Resectable Gallbladder Carcinoma: An Analysis of the Surveillance, Epidemiology, and End Results Database
Jisheng Zhu, Yunxiang Wu, Weidong Xiao, Yong Li
The American Surgeon™.2023; 89(5): 1629. CrossRef
Reappraisal of T1b gallbladder cancer (GBC): clinicopathologic analysis of 473 in situ and invasive GBCs and critical review of the literature highlights its rarity, and that it has a very good prognosis
Burcin Pehlivanoglu, Gizem Akkas, Bahar Memis, Olca Basturk, Michelle D. Reid, Burcu Saka, Nevra Dursun, Pelin Bagci, Serdar Balci, Juan Sarmiento, Shishir K. Maithel, Sudeshna Bandyopadhyay, Oscar Tapia Escalona, Juan Carlos Araya, Hector Losada, Michael
Virchows Archiv.2023; 482(2): 311. CrossRef
Subserosal vascular density predicts oncological features of T2 gallbladder cancer
Miho Akabane, Junichi Shindoh, Kei Kohno, Satoshi Okubo, Masaru Matsumura, Yutaka Takazawa, Masaji Hashimoto
Langenbeck's Archives of Surgery.2023;[Epub] CrossRef
Standardized lymph node dissection for gallbladder cancer under laparoscopy: en-bloc resection technique
Jian Cheng, Jie Liu, Chang-Wei Dou, Zhong-Chun Xie, Bing-Fu Fan, Li-Ming Jin, Lei Liang, Cheng-Wu Zhang
Langenbeck's Archives of Surgery.2023;[Epub] CrossRef
Development and validation of an online dynamic prognostic nomogram for incidental gallbladder adenocarcinoma patients without distant metastasis after surgery: a population-based study
Jie Chen, Yehong Han
Frontiers in Medicine.2023;[Epub] CrossRef
Effects of Cystic Duct Margin Involvement on the Survival Rates of Patients With Gallbladder Cancer: A Propensity Score-Matched Case-Control Study
Vasistha Jajal, Phani K Nekarakanti, Sugumaran K, Hirdaya Nag
Cureus.2023;[Epub] CrossRef
Laparoskopik Kolesistektomi Yapılan Hastalarda Rastlantısal Safra Kesesi Kanseri Sıklığı
Serkan ERKAN, Hakan YABANOĞLU
Harran Üniversitesi Tıp Fakültesi Dergisi.2023; 20(3): 593. CrossRef
Utility of 18-Flurodeoxyglucose Positron Emission Tomography-Computed Tomography (18FDG PET-CT) in Gallbladder Cancer: Experience from a Tertiary Care Hospital
Niharika Bisht, Nishant Lohia, Sankalp Singh, Arti Sarin, Abhishek Mahato, Dharmesh Paliwal, Indranil Sinha, Sharad Bhatnagar
World Journal of Nuclear Medicine.2023; 22(04): 276. CrossRef
Lymphadenectomy in gallbladder adenocarcinoma: Are we doing enough?
Marianna V. Papageorge, Susanna W.L. de Geus, Alison P. Woods, Sing Chau Ng, F. Thurston Drake, Andrea Merrill, Michael R. Cassidy, David McAneny, Jennifer F. Tseng, Teviah E. Sachs
The American Journal of Surgery.2022; 224(1): 423. CrossRef
Systematic review and meta-analysis of survival outcomes in T2a and T2b gallbladder cancers
Wasfi Alrawashdeh, Sivesh K. Kamarajah, Rohan R. Gujjuri, William A. Cambridge, Shailesh V. Shrikhande, Alice C. Wei, Mohamed Abu Hilal, Steve A. White, Sanjay Pandanaboyana
HPB.2022; 24(6): 789. CrossRef
Examination of the characteristics of long-term survivors among patients with gallbladder cancer with liver metastasis who underwent surgical treatment: a retrospective multicenter study (ACRoS1406)
Ryota Higuchi, Hiroaki Ono, Ryusei Matsuyama, Yusuke Takemura, Shinjiro Kobayashi, Takehito Otsubo, Yuta Abe, Itaru Endo, Minoru Tanabe, Masakazu Yamamoto
BMC Gastroenterology.2022;[Epub] CrossRef
Development and validation of a prognostic nomogram for gallbladder cancer patients after surgery
Xinsen Xu, Min He, Hui Wang, Ming Zhan, Linhua Yang
BMC Gastroenterology.2022;[Epub] CrossRef
Transcription factor 4 expression and correlation with tumor progression in gallbladder cancer
Kaushik Neogi, Mallika Tewari, Ashish Kumar Singh, Kavyanjali Sharma, Gullanki Naga Venkata Charan Tej, Sumit Singh Verma, Subash Chandra Gupta, Prasanta Kumar Nayak
Journal of Cancer Research and Therapeutics.2022; 18(3): 668. CrossRef
Postsurgical radiotherapy in stage IIIB gallbladder cancer patients with one to three lymph nodes metastases: A propensity score matching analysis
Yu-Long Cai, Yi-Xin Lin, Xian-Ze Xiong, Hui Ye, Fu-Yu Li, Nan-Sheng Cheng
The American Journal of Surgery.2021; 221(3): 642. CrossRef
S100P as a marker for poor survival and advanced stage in gallbladder carcinoma
Alka Mary Mathai, Jacob Alexander, Hsuan-Ying Huang, Chien-Feng Li, Yung-Ming Jeng, Kar-Ming Fung, William P. Harris, Paul E. Swanson, Camtu Truong, Matthew M. Yeh
Annals of Diagnostic Pathology.2021; 52: 151736. CrossRef
The 8th Edition American Joint Committee on Cancer Staging for Hepato-pancreato-biliary Cancer: A Review and Update
Xiaoyan Liao, Dongwei Zhang
Archives of Pathology & Laboratory Medicine.2021; 145(5): 543. CrossRef
Expression of HER2 and Mismatch Repair Proteins in Surgically Resected Gallbladder Adenocarcinoma
You-Na Sung, Sung Joo Kim, Sun-Young Jun, Changhoon Yoo, Kyu-Pyo Kim, Jae Hoon Lee, Dae Wook Hwang, Shin Hwang, Sang Soo Lee, Seung-Mo Hong
Frontiers in Oncology.2021;[Epub] CrossRef
Prognostic Significance of Tumor Location in T2 Gallbladder Cancer: A Systematic Review and Meta-Analysis
Hyun Kang, Yoo Shin Choi, Suk-Won Suh, Geunjoo Choi, Jae Hyuk Do, Hyoung-Chul Oh, Hong Jin Kim, Seung Eun Lee
Journal of Clinical Medicine.2021; 10(15): 3317. CrossRef
A Clinical-Radiomics Nomogram for Preoperative Prediction of Lymph Node Metastasis in Gallbladder Cancer
Xingyu Liu, Xiaoyuan Liang, Lingxiang Ruan, Sheng Yan
Frontiers in Oncology.2021;[Epub] CrossRef
Manejo endoscópico de adenocarcinoma de vesícula biliar. Presentación de caso
Cristina Fernández-González de la Vega, Víctor Hugo Hernández-Lozada
Revista Mexicana de Cirugía Endoscópica.2021; 22(1): 28. CrossRef

9,915 View
217 Download
34 Web of Science
32 Crossref

Prognosis of Pancreatic Cancer Patients with Synchronous or Metachronous Malignancies from Other Organs Is Better than Those with Pancreatic Cancer Only: Su-Jin Shin, Hosub Park, You-Na Sung, Changhoon Yoo, Dae Wook Hwang, Jin-hong Park, Kyu-pyo Kim, Sang Soo Lee, Baek-Yeol Ryoo, Dong-Wan Seo, Song Cheol Kim, Seung-Mo Hong; Cancer Res Treat. 2018;50(4):1175-1185. Published online December 20, 2017; DOI: https://doi.org/10.4143/crt.2017.494

Abstract PDF Supplementary Material PubReader ePub

Purpose
Pancreatic cancer associated double primary tumors are rare and their clinicopathologic characteristics are not well elucidated.
Materials and Methods
Clinicopathologic factors of 1,352 primary pancreatic cancers with or without associated double primary tumors were evaluated.
Results
Of resected primary pancreatic cancers, 113 (8.4%) had associated double primary tumors, including 26 stomach, 25 colorectal, 18 lung, and 13 thyroid cancers. The median interval between the diagnoses of pancreatic cancer and associated double primary tumors was 0.5 months. Overall survival (OS) of pancreatic cancer patients with associated double primary tumors was longer than those with pancreatic cancer only (median, 23.1 months vs. 17.0 months, p=0.002). Patients whose pancreatic cancers were resected before the diagnosis of metachronous tumors had a better OS than patients whose pancreatic cancer resected after the diagnosis of metachronous tumors (48.9 months and 13.5 months, p=0.001) or those whose pancreatic cancers were resected synchronously with non-pancreas tumors (19.1 months, p=0.043). The OS of pancreatic cancer patients with stomach (33.9 months, p=0.032) and thyroid (117.8 months, p=0.049) cancers was significantly better than those with pancreas cancer only (17.0 months).
Conclusion
About 8% of resected pancreatic cancers had associated double primary tumors, and those from the colorectum, stomach, lung, and thyroid were common. Patients whose pancreatic cancer was resected before the diagnosis of metachronous tumors had better OS than those resected after the diagnosis of metachronous tumors or those resected synchronously.

Citations

Citations to this article as recorded by

Laparoscopic Radical Total Gastrectomy and Pancreatosplenectomy for Synchronous Cancer of the Stomach and Pancreas
Motoki Ebihara, Kentoku Fujisawa, Shusuke Haruta, Hironori Uruga, Masaki Ueno
Cureus.2024;[Epub] CrossRef
Synchronous primary multiple cancer: distal cholangiocarcinoma of the intrapancreatic common bile duct and intraductal papillary mucinous tumor associated with ductal adenocarcinoma of the pancreatic tail
G.R. Setdikova, E.A. Stepanova, A.N. Verbovsky, A.V. Semenkov
Pirogov Russian Journal of Surgery.2024; (8): 57. CrossRef
Pancreatoduodenectomy after Ivor-Lewis Santi oesophagectomy with gastric tube reconstruction. An European multicentre experience
Alessandro D. Mazzotta, Pietro Addeo, Benedetto Ielpo, Michael Ginesini, Nicolas Regenet, Ugo Boggi, Philippe Bachellier, Olivier Soubrane
Surgical Oncology.2024; 57: 102144. CrossRef
The importance of hsa-miR-28 in human malignancies
Seyede Fatemeh Hosseini, Setareh Javanshir-giv, Hanieh Soleimani, Homa Mollaei, Farzad Sadri, Zohreh Rezaei
Biomedicine & Pharmacotherapy.2023; 161: 114453. CrossRef
Synchronous double primary malignancies of the pancreatic body and extrahepatic bile duct treated with pancreatoduodenectomy and splenic artery resection following neoadjuvant chemotherapy with gemcitabine plus nab-paclitaxel: a case report
Takahiro Murokawa, Takehiro Okabayashi, Kenta Sui, Motoyasu Tabuchi, Jun Iwata
Surgical Case Reports.2022;[Epub] CrossRef
A Descriptive Study of the Types and Survival Patterns of Saudi Patients with Multiple Primary Solid Malignancies: A 30-Year Tertiary Care Center Experience
Moustafa S. Alhamadh, Rakan B. Alanazi, Sultan T. Algarni, Ahmed Abdullah R. Alhuntushi, Mohammed Qasim Alshehri, Yusra Sajid Chachar, Mohammad Alkaiyat, Fouad Sabatin
Current Oncology.2022; 29(7): 4941. CrossRef
Synchronous Pancreatic Ductal Adenocarcinoma in the Head and Tail, a Double Trouble: A Case Report and Literature Review
Daniel Paramythiotis, Georgia Fotiadou, Eleni Karlafti, Ioanna Abba Deka, Georgios Petrakis, Elisavet Psoma, Xanthippi Mavropoulou, Filippos Kyriakidis, Smaro Netta, Stylianos Apostolidis
Diagnostics.2022; 12(11): 2709. CrossRef
Ergebnisse nach Pankreaseingriffen aus Sicht der Betroffenen: Versorgungsforschung der Selbsthilfegruppe „Arbeitskreis der Pankreatektomierten e. V.“
Ioannis Dimopoulos, Gabriele Meyer, Saleem Ibrahim Elhabash, Michele Sorleto, Carsten Gartung, Nils Ewald, Ulrich Klaus Fetzner, Lutz Otto, Friedhelm Möhlenbrock, Waldemar Uhl, Berthold Gerdes
Zeitschrift für Gastroenterologie.2021; 59(03): 214. CrossRef
An extremely atypical presentation of esophageal squamous cell carcinoma with pancreatic and hepatic metastases
Lei Zhang, Xin Long, Zheng-Nan Hu, Yu Wu, Jia Song, Bi-Xiang Zhang, Wei-Xun Chen
Medicine.2021; 100(20): e25785. CrossRef
Clinical features of patients with pancreatic ductal adenocarcinoma with a history of other primary malignancies: A retrospective analysis
Hironori Hayashi, Koji Amaya, Tomokazu Tokoro, Kosuke Mori, Shunsuke Takenaka, Yuya Sugimoto, Yuto Kitano, Toru Kurata, Shunsuke Kawai, Atsushi Hirose, Tomoya Tsukada, Masahide Kaji, Koichi Shimizu, Kiichi Maeda
Molecular and Clinical Oncology.2021;[Epub] CrossRef
A Rare Case of Synchronous Esophageal and Pancreatic Malignancy
Ali Khalifa, Arkady Broder
Cureus.2021;[Epub] CrossRef
Synchronous concomitant pancreatic acinar cell carcin and gastric adenocarcinoma: A case report and review of literature
Tian Fang, Ting-Ting Liang, Yi-Zhuo Wang, Hai-Tao Wu, Shu-Han Liu, Chang Wang
World Journal of Clinical Cases.2021; 9(28): 8509. CrossRef
A novel long non‑coding RNA TTN‑AS1/microRNA‑589‑5p/FOXP1 positive feedback loop increases the proliferation, migration and invasion of pancreatic cancer cell lines
Jing Zhao, Fang Wu, Jun Yang
Oncology Letters.2021;[Epub] CrossRef
Multiple primary gastrointestinal tumors of gastric, pancreatic and rectal origin; a case report
Abdullah Mohammed Aloraini, Hadeel Ayman Helmi, Nadia Abdulaziz Aljomah, Ahmad Mohmmed Zubaidi
International Journal of Surgery Case Reports.2021; 89: 106610. CrossRef
A Newly Developed Pancreatic Adenocarcinoma in a Patient with Advanced Thyroid Cancer under Long-Term Sorafenib Use
Min Ji Kim, Han-Sang Baek, Sung Hak Lee, Dong-Jun Lim
International Journal of Thyroidology.2021; 14(2): 175. CrossRef
Long noncoding RNA LINC00514 accelerates pancreatic cancer progression by acting as a ceRNA of miR-28-5p to upregulate Rap1b expression
Qing Han, Junhe Li, Jianping Xiong, Zhiwang Song
Journal of Experimental & Clinical Cancer Research.2020;[Epub] CrossRef
Molecular Characterization of a Long-Term Survivor Double Metastatic Non-Small Cell Lung Cancer and Pancreatic Ductal Adenocarcinoma Treated with Gefitinib in Combination with Gemcitabine Plus Nab-Paclitaxel and mFOLFOX6 as First and Second Line Therapy
Oronzo Brunetti, Giuseppe Badalamenti, Simona De Summa, Angela Calabrese, Antonella Argentiero, Livia Fucci, Vito Longo, Domenico Galetta, Pia Maria Soccorsa Perrotti, Rosamaria Pinto, Daniela Petriella, Katia Danza, Stefania Tommasi, Francesco Leonetti,
Cancers.2019; 11(6): 749. CrossRef

14,789 View
246 Download
17 Web of Science
17 Crossref

First
Prev
Page of 1
Next
Last

Search